37,110 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by PDT Partners LLC

PDT Partners LLC acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 37,110 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,157,000. PDT Partners LLC owned 0.07% of Supernus Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in SUPN. Armistice Capital LLC increased its position in shares of Supernus Pharmaceuticals by 47.6% during the second quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock valued at $141,026,000 after buying an additional 1,700,000 shares during the period. Pacer Advisors Inc. boosted its position in Supernus Pharmaceuticals by 100,186.3% during the 2nd quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock valued at $36,109,000 after acquiring an additional 1,348,508 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Supernus Pharmaceuticals by 369.1% during the 2nd quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company’s stock worth $13,419,000 after acquiring an additional 394,728 shares during the period. Renaissance Technologies LLC raised its position in shares of Supernus Pharmaceuticals by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after acquiring an additional 351,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Supernus Pharmaceuticals by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock valued at $76,690,000 after purchasing an additional 309,966 shares during the period.

Insider Activity

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 14,213 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the sale, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. This trade represents a 51.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the transaction, the senior vice president now directly owns 8,200 shares in the company, valued at $303,236. This trade represents a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 154,213 shares of company stock worth $5,660,180 in the last three months. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Trading Down 1.1 %

Shares of SUPN stock opened at $36.57 on Monday. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $39.37. The stock has a market capitalization of $2.02 billion, a P/E ratio of 34.18 and a beta of 0.86. The firm’s 50 day moving average is $34.20 and its 200 day moving average is $31.34.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.29) EPS. As a group, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.